The financials
Corcept Therapeutics Incorporated by the numbers
Corcept Therapeutics Incorporated (CORT) reported revenue of $165M in Q1 2026 (quarter ended March 31, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 98% and net loss of $32M. For the full year FY2025, revenue was $761M (+13% year on year) and net income $100M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $165M | $157M | +4.9% |
| Gross profit | $162M | $155M | +4.7% |
| Operating income | −$50M | $3.4M | to a loss |
| Net income | −$32M | $21M | to a loss |
| Diluted EPS | −$0.30 | $0.17 | to a loss |